Moss Adams Wealth Advisors LLC Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Moss Adams Wealth Advisors LLC bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 7,577 shares of the company's stock, valued at approximately $208,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in shares of BridgeBio Pharma by 5.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 73,230 shares of the company's stock valued at $1,855,000 after purchasing an additional 3,624 shares during the last quarter. Amalgamated Bank lifted its holdings in BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company's stock valued at $123,000 after buying an additional 962 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in BridgeBio Pharma by 18.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 10,202 shares of the company's stock valued at $258,000 after buying an additional 1,617 shares during the period. Ensign Peak Advisors Inc boosted its position in BridgeBio Pharma by 44.5% during the second quarter. Ensign Peak Advisors Inc now owns 1,646,202 shares of the company's stock valued at $41,698,000 after acquiring an additional 506,845 shares during the last quarter. Finally, Profund Advisors LLC grew its holdings in BridgeBio Pharma by 1.1% during the 2nd quarter. Profund Advisors LLC now owns 51,029 shares of the company's stock worth $1,293,000 after acquiring an additional 555 shares during the period. Institutional investors own 99.85% of the company's stock.

Insider Buying and Selling at BridgeBio Pharma

In related news, CEO Neil Kumar sold 27,389 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the transaction, the chief executive officer now directly owns 4,897,443 shares of the company's stock, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian C. Stephenson sold 4,156 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the sale, the chief financial officer now owns 93,758 shares of the company's stock, valued at $2,101,116.78. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.66% of the company's stock.

BridgeBio Pharma Stock Performance

Shares of BridgeBio Pharma stock traded down $0.32 on Monday, hitting $33.79. The company had a trading volume of 2,877,156 shares, compared to its average volume of 1,403,895. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of -14.02 and a beta of 1.05. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $41.04. The stock has a 50 day moving average of $27.67 and a 200-day moving average of $26.54.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BBIO shares. Scotiabank upped their target price on BridgeBio Pharma from $45.00 to $48.00 and gave the company a "sector outperform" rating in a research report on Monday, November 25th. Bank of America lifted their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. Oppenheimer began coverage on shares of BridgeBio Pharma in a research note on Thursday, October 3rd. They set a "market perform" rating on the stock. Evercore ISI lifted their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Monday, December 23rd. Finally, Leerink Partners dropped their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $48.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.